In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function

European Journal of Pharmacology

Volumn 483, Issue 1, 2004, Pages 45-53

  Jordan, Shaun ^a   Koprivica, Vuk ^a   Dunn, Robert ^a   Tottori, Katsura ^b   Kikuchi, Tetsuro ^b   Altar, C Anthony ^c  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^c Psychiatric Genomics Inc   (United States)

Author keywords

5 HT (5 hydroxytryptamine, serotonin); Antipsychotic; Dopamine; Prefrontal cortex; Schizophrenia; Striatum

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; ARIPIPRAZOLE; DOPAMINE; DOPAMINE 2 RECEPTOR; HOMOVANILLIC ACID; OLANZAPINE; PARTIAL AGONIST; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST;

AGONIST; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONSCIOUSNESS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BLOOD LEVEL; DOPAMINERGIC ACTIVITY; EXPERIMENTAL HOST; FOREBRAIN; IN VIVO CULTURE; MALE; MICRODIALYSIS; NONHUMAN; PREFRONTAL CORTEX; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE; SPECIES COMPARISON; STRIATE CORTEX;

EID: 0346096591     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.10.025     Document Type: Article

References (38)

1. 1A receptor ligand, lesopitron, on rat cortical 5-HT and dopamine turnover. Br. J. Pharmacol. 113:1994;425-430.
2. 2 receptors. J. Pharmacol. Exp. Ther. 302:2002;381-389.
3. Carson W., Cornblatt B., Saha A., Ali M., Kern R., Green M. Neurocognitive benefits of aripiprazole versus olanzapine in stable psychosis. Eur. Neuropsychopharmacol. 12:2002;S291.
4. Cartmell J., Salhoff C.R., Perry K.W., Monn J.A., Schoepp D.D. Dopamine and 5-HT turnover are increased by the mGlu2/3 receptor agonist LY379268 in rat medial prefrontal cortex, nucleus accumbens and striatum. Brain Res. 887:2000;378-384.
5. Clark D., Hjorth S., Carlsson A. Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity: I. Review of the evidence. J. Neural. Transm. 62:1985;1-52.
6. 1A agonist 8-OH-DPAT is given prior to stress. Brain Res. 755:1997;351-355.
7. Ferre S., Artigas F. Clozapine decreases serotonin extracellular levels in the nucleus accumbens by a dopamine receptor-independent mechanism. Neurosci. Lett. 187:1995;61-64.
8. Fujikawa M., Nagashima M., Inoue T., Yamada K., Furukawa T. Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats. Pharmacol. Biochem. Behav. 53:1996;903-909.
9. Fuller R.W., Perry K.W. Effects of buspirone and its metabolite, 1-(2-pyrimidinyl)piperazine, on brain monoamines and their metabolites in rats. J. Pharmacol. Exp. Ther. 248:1989;50-56.
10. Grady M.A., Gasperoni T.L., Kirkpatrick P. Fresh from the pipeline: aripiprazole. Nat. Rev., Drug Discov. 2:2003;427-428.
11. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76:2001;1521-1531.
12. Inoue T., Domae M., Yamada K., Furukawa T. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4- dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J. Pharmacol. Exp. Ther. 277:1996;137-143.
13. 1A receptor. Eur. J. Pharmacol. 441:2002;137-140.
14. 1A receptors. Eur. Neuropsychopharmacol. 12(3):2002;S293.
15. Kane J.M., Carson W.H., Saha A.R., McQuade R.D., Ingenito G.G., Zimbroff D.L., Ali M.W. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry. 63:2002;763-771.
16. 1A presynaptic, but not postsynaptic, receptor-mediated responses: relationship to antidepressant-like action. Eur. J. Pharmacol. 138:1987;53-60.
17. 2 receptor antagonistic activity. J. Pharmacol. Exp. Ther. 274:1995;329-336.
18. 2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities. Mol. Pharmacol. 42:1992;432-438.
19. Lawler C.P., Prioleau C., Lewis M.M., Mak C., Jiang D., Schetz J.A., Gonzalez A.M., Sibley D.R., Mailman R.B. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 20:1999;612-627.
20. Li X.M., Perry K.W., Wong D.T., Bymaster F.P. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology. 136:1998;153-161.
21. McQuade R.D., Burris K.D., Jordan S., Tottori K., Kurahashi N., Kikuchi T. Aripiprazole: a dopamine-serotonin system stabilizer. Int. Neuropsychopharmacol. 5(Suppl. 1):2002;S176.
22. Meller E., Bohmaker K., Namba Y., Friedhoff A.J., Goldstein M. Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Mol. Pharmacol. 31:1987;592-598.
23. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 21(Suppl. 2):1999;106S-115S.
24. Millan M.J., Rivet J.M., Canton H., Lejeune F., Bervoets K., Brocco M., Gobert A., Lefebvre de Ladonchamps B., Le Marouille-Girardon S., Verriele L., Laubie M., Lavielle G. S 14671: a naphthylpiperazine 5-hydroxytryptamine1A agonist of exceptional potency and high efficacy possessing antagonist activity at 5-hydroxytryptamine1C/2 receptors. J. Pharmacol. Exp. Ther. 262:1992;451-463.
25. Millan M.J., Lejeune F., Gobert A. Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J. Psychopharmacol. 14:2000;114-138.
26. 1A receptor antagonist (S)-UH-301 prevents (R)-8-OH-DPAT-induced decrease in interstitial concentrations of serotonin in the rat hippocampus. Eur. J. Pharmacol. 216:1992;373-378.
27. Pacchioni A.M., Gioino G., Assis A., Cancela L.M. A single exposure to restraint stress induces behavioral and neurochemical sensitization to stimulating effects of amphetamine: involvement of NMDA receptors. Ann. N.Y. Acad. Sci. 965:2002;233-246.
28. Pani L., Porcella A., Gessa G.L. The role of stress in the pathophysiology of the dopaminergic system. Mol. Psychiatry. 5:2000;14-21.
29. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 2nd ed. 1998;Academic Press, San Diego.
30. Protais P., Lesourd M., Comoy E. Similar pharmacological properties of 8-OH-DPAT and alnespirone (S 20499) at dopamine receptors: comparison with buspirone. Eur. J. Pharmacol. 352:1998;179-187.
31. Rayevsky K.S., Gainetdinov R.R., Grekhova T.V., Sotnikova T.D. Regulation of dopamine release and metabolism in rat striatum in vivo: effects of dopamine receptor antagonists. Prog. Neuropsychopharmacol. Biol. Psychiatry. 19:1995;1285-1303.
32. Semba J., Watanabe A., Kito S., Toru M. Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology. 34:1995;785-791.
33. Shapiro D.A., Renoc S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., Roth B.L., Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 28:2003;1400-1411.
34. 1A receptor antagonists on turnover and release of 5-HT in guinea-pig brain in vivo. Naunyn-Schmiedeberg's Arch. Pharmacol. 359:1999;110-116.
35. Volonte M., Monferini E., Cerutti M., Fodritto F., Borsini F. BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J. Neurochem. 69:1997;182-190.
36. Watanabe M., Hagino Y. The atypical antipsychotic sertindole enhances efflux of dopamine and its metabolites in the rat cortex and striatum. Eur. J. Pharmacol. 367:1999;19-23.
37. Westerink B.H., de Boer P., de Vries J.B., Kruse C.G., Long S.K. Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain. Eur. J. Pharmacol. 361:1998;27-33.
38. 3H]dopamine. Eur. J. Pharmacol. 155:1988;323-327.